Precipio Inc Cash Flow Conversion Efficiency
Precipio Inc cash flow conversion efficiency. Based on the latest financial reports, Precipio Inc (PRPO) has a cash flow conversion efficiency ratio of 0.001x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($10.00K) by net assets ($13.75 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Precipio Inc (1999–2024)
Cash flow conversion efficiency of Precipio Inc from 1999 to 2024. This chart illustrates how Precipio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Precipio Inc (PRPO) stock price for real-time trading data and today's change.
Precipio Inc Cash Flow Conversion Ratio Explained
Precipio Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Precipio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Precipio Inc ranked by their cash flow conversion efficiency. Also see Precipio Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lindeman Asia Investment Co. Ltd
KQ:277070
|
0.017x |
|
T S Flour Mill Public Company Limited
BK:TMILL
|
0.298x |
|
Fold Holdings, Inc. Class A Common Stock
NASDAQ:FLD
|
-0.302x |
|
Sung Bo Chem
KO:003080
|
-0.044x |
|
Bubang Co. Ltd
KQ:014470
|
0.043x |
|
Trimitra Prawara Goldland Tbk Pt
JK:ATAP
|
0.014x |
|
Hyunwoo Industrial Co. LTD
KQ:092300
|
0.056x |
|
AGROT
IS:AGROT
|
0.108x |
Annual Cash Flow Conversion Efficiency for Precipio Inc (1999–2024)
The table below shows the annual cash flow conversion efficiency of Precipio Inc from 1999 to 2024. Review Precipio Inc free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $12.09 Million | $439.00K | 0.036x | +114.72% |
| 2023-12-31 | $14.43 Million | $-3.56 Million | -0.247x | +47.71% |
| 2022-12-31 | $16.37 Million | $-7.72 Million | -0.472x | -76.47% |
| 2021-12-31 | $24.60 Million | $-6.58 Million | -0.267x | +49.08% |
| 2020-12-31 | $14.16 Million | $-7.43 Million | -0.525x | +24.17% |
| 2019-12-31 | $13.21 Million | $-9.14 Million | -0.692x | +37.24% |
| 2018-12-31 | $6.12 Million | $-6.75 Million | -1.103x | -114.76% |
| 2017-12-31 | $13.03 Million | $-6.69 Million | -0.514x | -379.96% |
| 2016-12-31 | $-19.35 Million | $-3.55 Million | 0.183x | -81.00% |
| 2015-12-31 | $-12.82 Million | $-12.38 Million | 0.966x | +146.18% |
| 2014-12-31 | $6.55 Million | $-13.70 Million | -2.091x | -182.46% |
| 2013-12-31 | $11.45 Million | $-8.47 Million | -0.740x | -47.08% |
| 2012-12-31 | $20.27 Million | $-10.20 Million | -0.503x | -2627.50% |
| 2011-12-31 | $11.05 Million | $220.00K | 0.020x | +109.85% |
| 2010-12-31 | $8.50 Million | $-1.72 Million | -0.202x | -286.04% |
| 2009-12-31 | $11.66 Million | $1.27 Million | 0.109x | +447.37% |
| 2008-12-31 | $13.21 Million | $-413.00K | -0.031x | +84.99% |
| 2007-12-31 | $14.10 Million | $-2.94 Million | -0.208x | -175.78% |
| 2006-12-31 | $16.04 Million | $-1.21 Million | -0.076x | +62.69% |
| 2005-12-31 | $17.91 Million | $-3.63 Million | -0.203x | +63.20% |
| 2004-12-31 | $16.54 Million | $-9.10 Million | -0.550x | -87.24% |
| 2003-12-31 | $45.06 Million | $-13.24 Million | -0.294x | -0.77% |
| 2002-12-31 | $61.51 Million | $-17.94 Million | -0.292x | -115.44% |
| 2001-12-31 | $82.10 Million | $-11.12 Million | -0.135x | -110.93% |
| 2000-12-31 | $73.97 Million | $-4.75 Million | -0.064x | -101.54% |
| 1999-12-31 | $-2.10 Million | $-8.74 Million | 4.165x | -- |
About Precipio Inc
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomar… Read more